The Company

It is Sangui BioTech's mission to develop innovative pharmaceuticals and medical products serving the biological regeneration of cells through compensatory supply of vital substrates to the human body: oxygen, glucose, glucosaccharides.

In pursuit of these goals, Professor Wolfgang K. Barnikol established the first Sangui Company in Mainz, Germany, in 1995.

At that time, two main projects had evolved from his earlier university and publicly funded studies:

  • the development of a haemoglobin based artificial oxygen carrier to be used as a life-saving blood additive in all cases of severe deficiencies of oxygen supply (e.g. as aligned with stroke, heart attack, lung shock etc.),
  • the development of an implantable glucose sensor based on photometric measurement helping diabetes patients to easily and continuously monitor their glucose level, hence improving their insulin and creating a better quality of life.

In order to obtain additional funding, in 1997 the company underwent a restructuring in the event of which Sangui BioTech International, Inc., a Colorado company, emerged (Certificate of Good Standing). As the parent company of the operating SanguiBioTech GmbH of Witten, Germany, it is traded on the electronic securities trading platform www.pinksheets.com (symbol: SGBI), as well as on the OTC market in Hamburg (WKN: 906757).

Like most biotech companies, Sangui BioTech International met increasing difficulties to address the capital market for additional funding after the decline of the markets since 2001. Unlike some biotech companies Sangui has been able to refocus its activities on products which promised to be marketable in the short term. These include:

  • PURE MO2ISTURE, an anti-aging cosmetic skin care product based on an innovative micro-emulsion,
  • HEMO2SPRAY. Based on Sangui's expertise in the field of artificial oxygen carriers, this haemoglobin spray facilitates oxygen diffusion from outside to the superficial cells of the wound ground, - a product which will eventually feature a new quality in the treatment of chronic wounds,
  • CHITOSKIN wound pads, demonstrating in all phases of wound healing not only the desired physical characteristics but also most favorable biological effects thus accelerating and enhancing the patients recovery.

Subsequent to a rigid cost cutting exercise and in the event of successful negotiations with industry partners for the development, clearance and distribution of our products it now appears that SanguiBiotech International, Inc., has an opportunity to successfully pursue its product business.

Sangui management is convinced that this may enable the company to finalize the preparations for the clinical test phases in the blood additive and glucose sensor projects.

 

Reminder: This company portrait as well as the other remarks on this website should be considered but a brief overview which should not serve as the basis for an investment decision. For more detailed information about the risks and opportunities related to our business please refer to our news & reports pages, in particular to our 10-QSB reports.